Author:
Lanzafame Massimiliano,Bonora Stefano,Lattuada Emanuela,Calcagno Andrea,Vento Sandro
Subject
Infectious Diseases,Microbiology (medical)
Reference11 articles.
1. Mutation associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients;Deschamps;J Antimicrob Chemother,2009
2. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48;Ortiz;AIDS,2008
3. TMC 1147 ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: A 14-day-proof-of-principle trial;Arasteh;AIDS,2005
4. Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIVinfected, treatment-experienced patients with no resistanceassociated mutations to darunavir;De Meyer;J Acquir Immune Defic Syndr,2008
5. Cahn P, Fourie J, Grinsztejn B, et al. Efficacy and safety of 48 weeks of once-daily vs twice daily DRV/r in treatment-experienced HIV-1+ patients with no DRV resistance-associated mutations:the ODIN trial 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, February 2010. [abstr 57].
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献